NYSEAMERICAN:IGC IGC Pharma (IGC) Stock Price, News & Analysis → Buy Friday, Sell Monday, No Exceptions (From DTI) (Ad) Free IGC Stock Alerts $0.40 -0.01 (-1.60%) (As of 04:37 PM ET) Add Compare Share Share Today's Range$0.39▼$0.4150-Day Range N/A52-Week Range$0.25▼$0.50Volume304,808 shsAverage Volume494,400 shsMarket Capitalization$25.49 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesOwnershipSEC FilingsShort Interest Get IGC Pharma alerts: Email Address Ad MarketBeatYour $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionStart Your Risk-Free Trial Here About IGC Pharma Stock (NYSEAMERICAN:IGC)IGC Pharma, Inc., a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63 that is in pre-clinical development. It also markets Holief, a wellness brand that targets women experiencing premenstrual syndrome and menstrual cramps. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.Read More IGC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IGC Stock News HeadlinesMarch 28, 2024 | msn.comAll About Kyle Richards' Mom Kathleen RichardsMarch 26, 2024 | businesswire.comIGC Pharma Announces $3 Million Unregistered Private Placement of its Common StockMarch 28, 2024 | Crypto 101 Media (Ad)Crypto Market Preps For Trillions Worth of Inflows! Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.March 23, 2024 | americanbankingnews.comIGC Pharma (NYSEAMERICAN:IGC) Share Price Passes Above 200 Day Moving Average of $0.00March 20, 2024 | msn.comAlzheimer's-Focused Small Cap Firm IGC Pharma Releases Data, Candidate Reduces Agitation Compared To PlaceboMarch 20, 2024 | msn.comEXCLUSIVE: Revolutionary Alzheimer's Drug By IGC Shows Early SuccessMarch 20, 2024 | finance.yahoo.comIGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s AgitationMarch 20, 2024 | businesswire.comIGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer's AgitationMarch 28, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.March 20, 2024 | businesswire.comIGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024March 12, 2024 | finance.yahoo.comIGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s PipelineMarch 12, 2024 | businesswire.comIGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer's PipelineFebruary 28, 2024 | marketwatch.comIGC Pharma Sees Positive Memory Function Data in Preclinical Study of Alzheimer's Disease DrugFebruary 28, 2024 | finance.yahoo.comPromising Results: TGR-63 Enhances Memory in Alzheimer's Mouse ModelFebruary 23, 2024 | finance.yahoo.comIGC Pharma Announces Equity Analyst Coverage by Ascendiant with a "Buy" Recommendation and $3.00 Price TargetFebruary 23, 2024 | businesswire.comIGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price TargetFebruary 19, 2024 | benzinga.comIGC Pharma Stock (AMEX:IGC) Dividends: History, Yield and DatesFebruary 19, 2024 | benzinga.comIGC Pharma Announces Q3 2024 Earnings: Strategic Patent Achievements Propel Forward Amid LossesFebruary 16, 2024 | finance.yahoo.comIGC Pharma Reports Third Quarter Fiscal 2024 ResultsFebruary 16, 2024 | businesswire.comIGC Pharma Reports Third Quarter Fiscal 2024 ResultsFebruary 1, 2024 | finance.yahoo.comIGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse ModelJanuary 23, 2024 | tmcnet.comIGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer'sJanuary 23, 2024 | benzinga.comWhy IGC Pharma Stock Is Moving HigherJanuary 23, 2024 | finance.yahoo.comIGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer’sJanuary 18, 2024 | msn.comIGC Pharma doses first patient with Alzheimer’s therapy at ClinCloudJanuary 17, 2024 | finance.yahoo.comIGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer’s TrialDecember 29, 2023 | msn.comIGC Pharma files for $100M mixed shelfSee More Headlines Receive IGC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IGC Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/14/2024Today3/28/2024Fiscal Year End3/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSEAMERICAN:IGC CUSIPN/A CIK1326205 Webwww.igcinc.us Phone(301) 983-0998Fax240-465-0273Employees61Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,510,000.00 Net Margins-1,163.24% Pretax Margin-1,163.24% Return on Equity-110.37% Return on Assets-93.34% Debt Debt-to-Equity Ratio0.02 Current Ratio1.85 Quick Ratio0.86 Sales & Book Value Annual Sales$910,000.00 Price / Sales28.01 Cash FlowN/A Price / Cash FlowN/A Book Value$0.28 per share Price / Book1.43Miscellaneous Outstanding Shares63,730,000Free Float51,625,000Market Cap$25.49 million OptionableNot Optionable Beta1.69 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Ram Mukunda (Age 65)President, CEO & Director Comp: $705kMs. Claudia Grimaldi (Age 53)VP, Principal Financial Officer, Chief Compliance Officer & Non-Independent Director Comp: $245kMr. Rohit Goel (Age 30)Senior Director of Accounting & Principal Accounting Officer Key CompetitorsAmarillo BiosciencesOTCMKTS:AMARForte BiosciencesNASDAQ:FBRXMEI PharmaNASDAQ:MEIPPalatin TechnologiesNYSEAMERICAN:PTNSensei BiotherapeuticsNASDAQ:SNSEView All Competitors IGC Stock Analysis - Frequently Asked Questions How have IGC shares performed in 2024? IGC Pharma's stock was trading at $0.3446 at the beginning of the year. Since then, IGC stock has increased by 16.1% and is now trading at $0.40. View the best growth stocks for 2024 here. Are investors shorting IGC Pharma? IGC Pharma saw a drop in short interest during the month of March. As of March 15th, there was short interest totaling 848,500 shares, a drop of 6.8% from the February 29th total of 910,700 shares. Based on an average daily volume of 471,200 shares, the days-to-cover ratio is presently 1.8 days. View IGC Pharma's Short Interest. How were IGC Pharma's earnings last quarter? IGC Pharma, Inc. (NYSEAMERICAN:IGC) issued its earnings results on Wednesday, February, 14th. The construction company reported ($0.09) EPS for the quarter. The construction company earned $0.20 million during the quarter. IGC Pharma had a negative net margin of 1,163.24% and a negative trailing twelve-month return on equity of 110.37%. What other stocks do shareholders of IGC Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other IGC Pharma investors own include GW Pharmaceuticals (GWPH), Alibaba Group (BABA), Tilray (TLRY), Cronos Group (CRON), Micron Technology (MU), NewAge (NBEV), Advanced Micro Devices (AMD), Ford Motor (F) and NIO (NIO). Who are IGC Pharma's major shareholders? IGC Pharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of IGC Pharma? Shares of IGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:IGC) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford ClubFed launches fourth dollar overhaulStansberry ResearchSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IGC Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.